Kalaris Therapeutics Competitors and Similar CompaniesClear all
Kalaris Therapeutics's competitors and similar companies include Vir Biotechnology, Fate Therapeutics, Adaptive Biotechnologies and Neurocrine Biosciences.
 Kalaris Therapeutics Kalaris Therapeutics (formerly known as AlloVir and ViraCyte) is a company that develops and delivers transformative cell therapies for patients suffering from life-threatening virus-associated diseases. |  Vir Biotechnology Vir Biotechnology is a biopharmaceutical company that develops therapies for infectious diseases and cancer. |  Fate Therapeutics Fate Therapeutics is a stem cell and developmental biology research company using biological mechanisms to develop stem cell therapeutics. |  Adaptive Biotechnologies Adaptive Biotechnologies (formerly known as Adaptive TCR) is a company that develops diagnostics and therapeutic tools based on the immune response to disease. |  Neurocrine Biosciences Neurocrine Biosciences is a biotechnology company focused on neurologic, psychiatric and endocrine-related disorders. | |
Founding Date | Founding Date 2013 | Founding Date 2016 | Founding Date 2007 | Founding Date 2009 | Founding Date 1992 |
Type | Type Public | Type Public | Type Public | Type Public | Type Public |
Tags | |||||
Locations | Locations Waltham, US HQ Dublin, IE Milan, IT | Locations San Francisco, US HQ Bellinzona, CH | Locations San Diego, US HQ San Diego, US | Locations Seattle, US HQ New York, US South San Francisco, US | Locations San Diego, US HQ |
Employees | Employees 695% decrease | Employees 40830% decrease | Employees 17871% increase | Employees 70910% decrease | Employees 70020% increase |
Valuation ($) | Valuation ($) 103.1 m | Valuation ($) 1 b | Valuation ($) 309.7 m | Valuation ($) 694.6 m | Valuation ($) 11.7 b |
Financial | |||||
Revenue (est.) | Revenue (est.) N/A | Revenue (est.) $68.6m (FY, 2025) | Revenue (est.) $6.6m (FY, 2025) | Revenue (est.) $277m (FY, 2025) | Revenue (est.) $2.9b (FY, 2025) |
Cost of goods | Cost of goods N/A | Cost of goods $26k (FY, 2025) | Cost of goods N/A | Cost of goods $71.4m (FY, 2025) | Cost of goods $52.1m (FY, 2025) |
Gross profit | Gross profit N/A | Gross profit $68.5m (FY, 2025) | Gross profit N/A | Gross profit $205.6m (FY, 2025) | Gross profit $2.8b (FY, 2025) |
Net income | Net income ($43.4m) (FY, 2025) | Net income ($438m) (FY, 2025) | Net income ($136.3m) (FY, 2025) | Net income ($59.5m) (FY, 2025) | Net income $478.6m (FY, 2025) |
Operating ⚠ | |||||
Patents (US) | Patents (US) 2 (Jul, 2020) | Patents (US) 1 (Oct, 2019) | Patents (US) N/A | Patents (US) N/A | Patents (US) N/A |
Funding | |||||
Total funding raised | Total funding raised $ 159m | Total funding raised $ 637.7m | Total funding raised $ 330.2m | Total funding raised $ 525m | Total funding raised $ 10m |
For sources of this data, please see the company profile
View Company Profiles
Vir Biotechnology
HQ
San Francisco, US
Employees
408↓ 30% decrease
Vir Biotechnology is a biopharmaceutical company that develops therapies for infectious diseases and cancer.
View companyFate Therapeutics
HQ
San Diego, US
Employees
178
Fate Therapeutics is a stem cell and developmental biology research company using biological mechanisms to develop stem cell therapeutics.
View companyAdaptive Biotechnologies
HQ
Seattle, US
Employees
709↓ 10% decrease
Adaptive Biotechnologies (formerly known as Adaptive TCR) is a company that develops diagnostics and therapeutic tools based on the immune response to disease.
View companyNeurocrine Biosciences
HQ
San Diego, US
Employees
700↑ 20% increase
Neurocrine Biosciences is a biotechnology company focused on neurologic, psychiatric and endocrine-related disorders.
View company